Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Farsightedness of Refractec

This article was originally published in Start Up

Executive Summary

Presbyopia is causing a rapprochement between two distinct types of ophthalmic surgeons--the cataract surgeon implanting intraocular lenses in the elderly, and the refractive surgeon offering private-pay laser vision correction procedures to young adults. Bridging the gap is Refractec, the first company to ever get FDA approval for an ophthalmic surgery technology specifically for presbyopia. Refractec offers a non-cutting treatment that surgeons regard as a "starter treatment" that gets new kinds of patients into refractive surgery practices.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts